Cowen

Bevi develops bottle-less water dispensers for offices and commercial spaces that dispense beverages made from filtered tap water with natural flavors, including real fruit essences. The systems allow users to customize drinks and view nutrition information, while the company emphasizes tracking environmental impact and reducing waste from bottled beverages. The technology is designed to run on the municipal water supply, aiming to transform beverage delivery by offering eco-friendly, healthy hydration options on site.

PolySign develops digital asset infrastructure for financial institutions to securely custody, store, transfer, and pay with digital assets. The platform combines proprietary blockchain technology with strong security and scalable architecture to support asset storage, settlement, and payments, featuring advanced encryption and seamless interoperability across networks. It is designed to integrate with existing financial organizations and global markets, enabling institutions to safeguard digital assets, streamline operations, and participate in modern capital markets while adhering to regulatory standards.

Portico Capital is the leading investment bank exclusively serving the Information and Business Services/Software industry. They have offices in the US and UK and have represented companies throughout the world.

Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Digital Prime Technologies offers customizable prime brokerage technology solutions for financial institutions. Its user-friendly interface combines API and SaaS products to connect clients with multiple liquidity providers for digital asset transactions, borrowing, lending, and collateral management.

AlphaSense is a market intelligence platform that helps research and business professionals discover, navigate, and monitor financial data and disclosures. The web-based platform collects data from filings, research, news, and other sources and makes it searchable through artificial intelligence and natural language processing, enabling users to search, set alerts, and analyze data points with accuracy. It serves a large enterprise base, including financial institutions and a majority of S&P 500 clients. Headquartered in New York, the company also operates offices in London, Helsinki, and Pune.

Quip NYC, Inc., operating as quip, is an oral healthcare company based in Brooklyn, New York, founded in 2014. The company designs, manufactures, and sells a range of oral care products, including electric toothbrushes, toothpastes, refillable floss pick and string, as well as various supplies such as toothbrush heads and travel covers. Quip is notable for being a pioneer in the direct-to-consumer oral care subscription model, providing customers with fresh supplies delivered every three months. In addition to its product offerings, quip also delivers oral care advice and is developing a technology platform to connect users with a network of dental professionals. Through its online platform, quip aims to make oral health simpler, more accessible, and enjoyable for consumers.

ecoATM, LLC specializes in the recycling of electronic devices, such as cell phones, MP3 players, and tablets, through a network of automated kiosks located across the United States. Founded in 2008 and based in San Diego, California, the company allows consumers to conveniently sell their unwanted devices for cash on the spot. The kiosks evaluate the worth of these used electronics, facilitating a quick and secure transaction process. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing its offerings to include both in-person kiosk transactions and online sales options through Gazelle.com. Consumers can trade in their devices for immediate cash and access certified pre-owned electronics at competitive prices. Through its commitment to convenience and sustainability, ecoATM promotes smart consumption by providing a reliable platform for recycling and purchasing electronic devices.

PolySign develops digital asset infrastructure for financial institutions to securely custody, store, transfer, and pay with digital assets. The platform combines proprietary blockchain technology with strong security and scalable architecture to support asset storage, settlement, and payments, featuring advanced encryption and seamless interoperability across networks. It is designed to integrate with existing financial organizations and global markets, enabling institutions to safeguard digital assets, streamline operations, and participate in modern capital markets while adhering to regulatory standards.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Proterra Inc. is a manufacturer of zero-emission electric buses, primarily focused on providing sustainable transportation solutions for public and commercial transit. Founded in 2004 and headquartered in Burlingame, California, with additional offices in Greenville, South Carolina, and City of Industry, California, Proterra designs its products, including 35-foot and 40-foot electric buses, to meet the diverse needs of urban and regional transit routes. The company's Catalyst platform is noted for its modularity, allowing it to adapt to various operational demands while delivering high energy efficiency. Proterra also offers a broad range of services, including vehicle electrification solutions, fleet planning, charging infrastructure, and comprehensive vehicle maintenance programs. By facilitating the transition away from fossil fuels, Proterra aims to enhance environmental quality and reduce operational costs for fleet operators, contributing to significant reductions in greenhouse gas emissions.

Kyber Data Science LLC is a subsidiary of Cowen Inc. focused on developing and selling unique and proprietary datasets across a variety of sectors to institutional investors and corporations.

ecoATM, LLC specializes in the recycling of electronic devices, such as cell phones, MP3 players, and tablets, through a network of automated kiosks located across the United States. Founded in 2008 and based in San Diego, California, the company allows consumers to conveniently sell their unwanted devices for cash on the spot. The kiosks evaluate the worth of these used electronics, facilitating a quick and secure transaction process. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing its offerings to include both in-person kiosk transactions and online sales options through Gazelle.com. Consumers can trade in their devices for immediate cash and access certified pre-owned electronics at competitive prices. Through its commitment to convenience and sustainability, ecoATM promotes smart consumption by providing a reliable platform for recycling and purchasing electronic devices.

Cowen Inc., established in 1918, is a global financial services firm headquartered in New York. It offers a broad range of services, including investment banking, research, sales and trading, prime brokerage, and investment management. Cowen's investment banking division provides capital raising, strategic advisory, and M&A services to public and private companies across various sectors such as healthcare, technology, and consumer. Its trading division facilitates the trading of financial instruments on behalf of institutional clients, while its prime brokerage services cater to the needs of hedge funds and other institutional investors. Additionally, Cowen's investment management arm offers actively managed alternative investment products. Through its subsidiaries, Cowen also provides services to middle-market companies in Europe, focusing on M&A and capital raising.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

ConvergEx is a technology firm that specializes in providing essential software products and technology-enabled services to a broad range of clients, totaling over 6,000 across 100 markets. Its diverse clientele primarily consists of asset managers and financial intermediaries, which includes investment advisors, hedge funds, mutual funds, plan sponsors, trust banks, family offices, separately managed accounts, broker-dealers, exchanges, alternative trading systems, and investment banks. ConvergEx's offerings are designed to support the critical operational needs of these financial entities, enabling them to enhance their performance and efficiency in a competitive landscape.

CEFC China Energy Company Limited is a private collective enterprise primarily engaged in energy and financial services. The company focuses on investing in oil and gas development and operates various subsidiaries that manage oil and gas terminals, including refineries and gas stations. CEFC China aims to enhance international economic cooperation in the energy sector while also working to establish a structured international investment bank and investment group. Through its diversified operations, CEFC China seeks to strengthen its presence in the global energy market.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Livongo Health, Inc. is a consumer digital health company that specializes in providing an integrated suite of solutions for individuals managing chronic conditions, particularly diabetes. Established in 2008 and headquartered in Mountain View, California, Livongo utilizes real-time data capture and analytics to promote health behavior change through its platform, which includes cellular-connected devices, supplies, coaching, and insights driven by data science. Its product offerings encompass Livongo for diabetes, hypertension, prediabetes and weight management, and behavioral health through its myStrength platform. The company serves a diverse client base, including employers, health plans, government entities, and labor unions, primarily within the United States. Livongo aims to enhance the experience of individuals with chronic conditions by providing timely, personalized support and information, ultimately leading to improved health outcomes. In 2020, Livongo became a subsidiary of Teladoc Health, Inc.

Quarton Partners, based in Birmingham, Michigan, is a leading middle-market investment banking firm offering mergers & acquisitions advisory, private capital raising, and other financial services. With extensive global experience, its principals have successfully completed numerous engagements across diverse industries such as business services, consumer products, healthcare, and industrial manufacturing.

Blue Corporate Finance, founded in 2001 and based in Munich, Germany, was a prominent independent advisory firm specializing in corporate finance for mid-sized transactions in Europe. The firm provided expert guidance to entrepreneurs, companies, and investors on various financial matters, including mergers and acquisitions, management buyouts, capital raising, and restructuring. Throughout its operation, Blue Corporate Finance successfully advised 180 clients on transactions totaling over 4 billion euros. In 2015, the firm merged with Quarton Partners, resulting in the formation of Quarton International, thereby expanding its reach and capabilities in the financial advisory sector.

Conifer Securities is a company that was acquired by Cowen Group in 2015

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

Maxwell Technologies develops, manufactures, and markets energy storage and power delivery solutions. Their products cater to diverse industries such as automotive, heavy transportation, renewable energy, backup power, wireless communications, and industrial electronics.

Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Echo Global Logistics is a prominent provider of technology-enabled transportation and supply chain management services. The company specializes in offering multimodal shipping options and asset-light third-party logistics services, including intermodal and international air and ocean freight forwarding. By leveraging proprietary web-based technology, dedicated service teams, and strong procurement capabilities, Echo Global Logistics helps clients achieve significant transportation savings while delivering high-quality service. This focus on efficiency and competitive pricing positions the company as a valuable partner in addressing clients' logistics needs.

Seabridge Gold Inc. is a development-stage company focused on the acquisition and exploration of gold properties primarily in North America. The company boasts one of the largest resources of gold, copper, and silver globally, with key projects including the Kerr-Sulphurets-Mitchell property in British Columbia, the Courageous Lake property in the Northwest Territories, and the 3 Aces Project in Yukon. Seabridge aims to enhance shareholder value by increasing resource and reserve ownership per share through a systematic approach: acquiring deposits, expanding them via exploration, converting them into reserves through engineering, and potentially partnering with established producers for mine construction. The company is committed to environmental stewardship and community engagement, striving to minimize its ecological impact while supporting local communities.

Aptose Biosciences is a clinical-stage biotechnology company focused on discovering and developing personalized cancer therapies. Its pipeline includes small molecule drugs designed for single-agent efficacy and to enhance the effectiveness of other anti-cancer treatments, without overlapping toxicities.

Sunworks is focused on advancing solar technology through the development of innovative 3-dimensional solar cell designs. This approach aims to enhance the conversion efficiency of sunlight into electricity, addressing the significant losses associated with conventional solar cells, which can reflect up to 30% of incident sunlight and lose more within the material itself. By employing light management techniques inspired by fiber optic technology, these next-generation solar cells are engineered to trap sunlight within micro-photovoltaic structures, allowing photons to bounce until converted into electrons. The anticipated result is a solar cell that operates with greater efficiency, consequently reducing the cost per watt and making solar energy more accessible and affordable for a broader audience.

InterDigital designs and develops advanced digital wireless technology solutions, with a focus on wireless, video, Artificial Intelligence, and related technologies. It generates revenue primarily through fixed-fee patent license agreements, operating in the United States, China, South Korea, Japan, Taiwan, and Europe.

Sesen Bio, Inc. is a late-stage clinical company based in Cambridge, Massachusetts, that focuses on the design, development, and commercialization of targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy currently in phase 3 clinical trials aimed at treating high-risk non-muscle invasive bladder cancer. Additionally, Sesen Bio is developing VB6-845d, a systemically-administered product for various EpCAM-positive solid tumors. The company is also exploring combination therapies, including Vicinium with Durvalumab for high-risk non-muscle invasive bladder cancer and another combination for squamous cell carcinoma of the head and neck. Sesen Bio has partnered with Leiden University Medical Center to co-develop an imaging agent. Established in 2008 and previously known as Eleven Biotherapeutics, Sesen Bio has developed a proprietary platform that combines antibody fragments with cytotoxic proteins to create innovative therapies.

Blueprint Medicines is a Cambridge, Massachusetts-based biopharmaceutical company that develops targeted, small-molecule therapies to treat genomically defined cancers, rare diseases, and related conditions. The company focuses on precision medicines that address molecular drivers and resistance mechanisms, advancing a pipeline that includes avapritinib for systemic mastocytosis and certain gastrointestinal stromal tumors, BLU-263, a KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders, fisogatinib for advanced hepatocellular carcinoma, and pralsetinib, a RET inhibitor for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. It is also pursuing BLU-782, an ALK2 inhibitor in early clinical trials for fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with partner companies such as Clementia Pharmaceuticals, CStone Pharmaceuticals, Genentech, and Hoffmann-La Roche. Founded in 2008, the company operates in the United States and Europe and combines its Insights-to-Validation platform with a proprietary chemical library to discover and develop new therapeutic compounds and combination therapies in oncology, hematology, and related areas.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Horizon Therapeutics is a biopharmaceutical company based in Northbrook, Illinois, established in 2005. The company specializes in developing prescription drugs aimed at providing relief for mild to moderate pain and managing arthritis. Among its notable product candidates are HZT-501, a proprietary fixed-dose combination of a nonsteroidal anti-inflammatory drug (NSAID) and ibuprofen, and HZT-602, which is a combination oral medication that includes naproxen and famotidine.

GlassesOff is a health care technology company based in Hod Hasharon, HaMerkaz, that specializes in developing consumer-oriented software applications aimed at enhancing near vision sharpness. Founded in 2007, the company has created a non-invasive solution for individuals suffering from presbyopia, enabling them to reduce their reliance on reading glasses. Utilizing its proprietary technology platform, GlassesOff offers a personalized program that monitors users' performance and progress in addressing symptoms such as blurred near vision, eye fatigue, headaches, and slow reading. The software employs exercises designed to improve the image processing function in the visual cortex of the brain, thereby enhancing users' reading capabilities without altering the optical characteristics of the eye.

Dahlman Rose & Company, LLC was a research-driven investment bank that specialized in the transportation, infrastructure, and natural resources sectors of the global supply chain. Founded in 2004 and headquartered in New York, the firm provided a range of services including institutional sales and trading, equity and fixed income research, mergers and acquisitions advisory, and underwriting. Dahlman Rose had a strong focus on sector specialization, particularly in areas such as marine shipping, offshore services, oil and gas exploration and production, oilfield services, and various modes of freight transport. The firm also maintained offices in Boston, Houston, and San Francisco, serving clients both domestically and internationally. In 2013, Dahlman Rose was acquired by Cowen Group, Inc.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapeutic products for cancer treatment. The company's lead product candidate, tucatinib, is an oral, HER2-selective small molecule tyrosine kinase inhibitor currently undergoing two Phase Ib clinical trials for metastatic breast cancer in combination therapies. In addition to tucatinib, Cascadian Therapeutics is advancing its preclinical pipeline, which includes CASC-578, a Chk1 cell cycle inhibitor, and CASC-674, an antibody targeting immuno-oncology. The company has established collaborative agreements with Array BioPharma for tucatinib development, Sentinel Oncology for novel Chk1 inhibitors, and Adimab for discovering new antibodies targeting immunotherapy in oncology. Founded in 1985 and formerly known as Oncothyreon Inc., Cascadian Therapeutics continues to focus on providing targeted therapies that aim to improve cancer treatment outcomes.

Aurora Flight Sciences is a company that specializes in the design and manufacture of unmanned systems and aerospace vehicles for both commercial and military applications. Headquartered in Manassas, Virginia, the company operates production facilities in Bridgeport, West Virginia, and Columbus, Mississippi, alongside a Research and Development Center in Cambridge, Massachusetts. Aurora focuses on advancing the future of flight through innovations in aircraft configurations, autonomous systems, propulsion technologies, and manufacturing processes. The company is particularly known for its high-altitude, long-endurance autonomous aircraft and develops advanced technologies in autonomy, propulsion, and composite materials tailored for government and commercial airline sectors.

Reef is a provider of internet software applications for the management of e-business.

Nextest Systems Corporation, founded in 1997, specializes in the design and manufacture of automatic test equipment (ATE) for non-volatile memory, microcontrollers, ASICs, and system-on-a-chip (SoC) semiconductors. The company is recognized as a low-cost leader in its field, addressing the increasing demand for testing solutions that enhance throughput, reliability, functionality, and capacity while simultaneously reducing time to market and testing costs. With a global workforce of approximately 150 employees, Nextest maintains sales and support offices worldwide and has successfully shipped over 1,000 systems to customers around the world.

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

SiberCore Technologies Incorporated is a pure-play, Internet IC company developing high-value-added Application Specific Standard Products (ASSPs) for intelligent hardware-based switching and routing platforms, such as Gigabit / Terabit Routers and Layer 2 / 3 / 4 Ethernet Switches. The company's initial products are a family of high-speed high-capacity packet forwarding engines based on Content Addressable Memories (CAM technology) which overcome the performance bottleneck associated with the network's routing table look-up function. This emerging market has been created by the demands of the explosion in datacom traffic, coupled with the worldwide deployment of fiber optics and DWDM. These broadband deployments have shifted the bottleneck from the Access and Transport section of the network, to the Routers and Switches connecting to these pipes. The company's founding technical team gained industry-wide recognition for its world-class design expertise in this area at Nortel Networks. A veteran Executive team in all the functional divisions of the company supplements this preeminent technical team.

TelOptica was funded in 1999 by communications network experts in optical, next-generation network design engineering and in operations research and algorithm development. The TelOptica team today includes highly regarded technologists with experience from established telco giants such as MCI and Sprint, international original equipment manufacturers such as Alcatel / DSC, Nortel, and IBM, and management consulting firms including McKinsey and Associates and Carreker Corporation. TelOptica is a well-funded, fast growing, privately held, optical communications technology company. TelOptica incorporated in Texas , received initial funding and support from the Startech business incubator of Richardson, Texas, and closed on its second round of funding from Trellis Partners, Austin Ventures, Centerpoint Ventures, SSM Ventures of Austin, and SG Cowen in June 2001.

The company provides enterprise portal software for the deployment and management of Intranet and extranet portals. The company's Coreport enterprise portal software allows businesses to provide all their stakeholders with a single, secure point of unified and personalized access to content, applications, processes, and services from any wired or wireless device.

Founded in 1993, ThoughtWorks is a global technology consultancy that combines strategy, design, and software engineering to help organizations succeed as modern digital businesses. It offers services such as enterprise modernization, platform and cloud solutions, customer experience design, and product development.

With more than 15 million page-views and more than 700,000 unique users per month, IPO.COM is the leading Internet provider of content and services to investors interested in initial public offerings, private placements and emerging growth companies. The company provides comprehensive IPO content including offering summaries, up-to-date pricing and filings, searchable EDGAR documents, daily columns and free weekly e-mail newsletters through the company's interactive portal and more than 150 financial web sites. Privately held, IPO.COM has offices in New York, Pennsylvania and California.

Tripod develops web publishing tools based in Williamstown, Massachusetts. It offers user-friendly platforms for creating fully functional websites with professional templates and powerful plugins, enabling clients to enhance their sites' functionality.